Slides
Page 1
© 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. 1 ASCO 2025 Panel Discussion May 31,2025
Page 2
© 2025, Iovance Biotherapeutics, Inc. 2 Forward-Looking StatementsCertain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration (“FDA”) approval, and Proleukin, for which we have obtained FDA and European Medicines Agency (“EMA”) approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this presentation assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this presentation; and no material fluctuation in exchange rates.
Page 3
© 2025, Iovance Biotherapeutics, Inc. 3 Agenda KOL Panel Discussion – Q&A – Iovance Leadership & KOL Panelists Introduction – Dan Kirby, Chief Commercial Officer Dr. Dan Olson, University of Chicago Dr. Geoffrey Gibney, Georgetown University Dr. Bruce Brockstein, Endeavor Health, Northshore
Page 4
© 2025, Iovance Biotherapeutics, Inc. 4 Global Leadership in Innovating, Developing and Delivering TIL Cell Therapy for Patients with Cancer Commercial Launch PipelineMarket Access >1,000 Commercial & clinical patients treated with Iovance products >80* >300 3 1 1DESIGNATIONS Fast Track BTD RMAT Authorized Treatment Centers as of 5/08/25 Global Advanced Melanoma Patient Treatment Opportunity 70K+ Clinical Trials1 11 Ex-U.S. Regulatory Filings Accepted2 3 ~3 weeks 250M+ Typical time to financial clearance Patient lives covered; Majority of patients have private coverage of Amtagvi patients covered by private payers 75%+ Patients Treated Approved Products: 2 1. Iovance sponsored clinical trials, does not include expanded access or investigator sponsored studies. *Includes centers in final stages of readiness, soon to be authorized or planned. Abbreviations: BTD=Breakthrough Therapy Designation; FDA=U.S. Food and Drug Administration; RMAT=Regenerative Medicine Advanced Therapy Designation
Page 5
© 2025, Iovance Biotherapeutics, Inc. 5 Amtagvi® Delivered Deep & Durable Responses 1. Medina et al, ASCO 2025 CI, confidence interval; mDOR, median duration of response; NR, not reached. •Meaningful overall survival benefit •Deepening responses observed over time •No new or late-onset adverse events 4 ~20% 5 Year Overall Survival (n=153) (95% CI, 4.1, NR) ORR 31.4%(95% CI: 24.1, 39.4) mDOR 36.5 months (95% CI: 8.3, NR) Median study follow up: 57.8 months 5 Year Analysis of Amtagvi Showed Long Term Benefit (N=153)1 ~1/3 of responders had ongoing responses at 5 years
Page 6
© 2025, Iovance Biotherapeutics, Inc. 6 1. The Leukemia & Lymphoma Society. Facts About Hematopoietic Stem Cell Transplant (HSCT). September 2023. Accessed May 8, 2025. https://www.lls.org. 2. National Cancer Institute. National Institutes of Health. Milestones in Cancer Research and Discovery. Updated April 18, 2025. Accessed May 8, 2025. https://www.cancer.gov/ research/progress/250-years-milestones. 3. Waldmann TA. Cold Spring Harb Perspect Biol. 2018;10(12):a028472. 4. Cruz E, Kayser V. Biologics. 2019;13:33-51. doi:10.2147/BTT.S166310. 5. Cheever MA. Clin Cancer Res. 2011;17(11):3520-3526. 6. Sarnaik AA, et al. J Clin Oncolo. 2021;39(24):2656-2666. TIL Cell Therapy,5 Individualized T cells to harness the power of the body’s own immune system to fight cancer 2010 1998 2011 1980s 2024+ Cytokine Therapy2,3 Broad immune activation, high toxicity HSCT1 Allogeneic and autologous bone marrow transplant, full immune system reset Monoclonal Antibodies1,4 Beginning of receptor-targeted precision medicine Therapeutic Cancer Vaccines5 Customized vaccines & immune redirection Checkpoint Inhibitors4 T cell reinvigoration, survival boost CAR T cell therapy1 Engineered, targeted T cells: supercharged immune response 1992 2017 A future defined by cell therapy.
Page 7
© 2022, Iovance Biotherapeutics, Inc. 7 KOL Panel Dan Olson, M.D. Medical Oncologist University of Chicago Bruce Brockstein, M.D. Medical Oncologist Endeavor Health, Northshore Geoffrey T. Gibney, M.D. Medical Oncologist Georgetown University
Page 8
© 2025, Iovance Biotherapeutics, Inc. 8 Q&A
Page 9
© 2025, Iovance Biotherapeutics, Inc. © 2025, Iovance Biotherapeutics, Inc. 9 Thank you.